Moderna and Merck report interim results from their first large-scale late-stage trial of a personalized mRNA cancer vaccine for melanoma. The regimen pairs a made-to-order vaccine with Merck’s Keytruda (pembrolizumab) and is designed for patients whose melanoma has been surgically removed.
Across sources, the companies say the combination improves outcomes compared with Keytruda alone, including extending the time patients live without their cancer returning. Quartz and CNBC both note that the study includes more than 1,100 patients, and that the results show reduced melanoma recurrence in this group.
The Globe and Mail highlights market reaction, stating that Moderna shares rise on the interim findings. While outlets focus on different angles—trial size and effect on recurrence versus broader business impact—none of the summaries contradict the core reported benefit: the personalized vaccine plus Keytruda performs better than Keytruda alone in delaying disease recurrence.
